Abbott Gains 1.31% Amid 140th Trading Volume Rank as Analysts Weigh Diagnostic Sector Growth and Competitive Risks

Abbott (ABT) rose 1.31% on July 29, 2025, with a trading volume of $0.74 billion, down 27.97% from the previous day, ranking 140th in market activity. The stock’s performance coincided with multiple industry-specific market forecasts and analyst updates that highlight its position in diagnostic and medical device sectors.

Recent reports indicate strong growth potential for Abbott’s diagnostic and testing divisions. The global drug abuse testing market is projected to reach $12.77 billion by 2033, driven by rising awareness and regulatory enforcement. Abbott is positioned as a key player alongside firms like Thermo Fisher and Roche. Similarly, the European defibrillator market, valued at $3.87 billion in 2024, is expected to grow at a 7.2% CAGR through 2033, with Abbott competing against Medtronic and Philips in this critical healthcare segment.

Analyst activity also underscored mixed signals for the stock. Leerink Partners reduced its price target to $136 from $143 while maintaining a Hold rating, citing competitive pressures. Conversely, RBC Capital reaffirmed an Outperform rating, raising its target to $147, emphasizing Abbott’s revenue and earnings growth potential. Meanwhile, Revvity’s downward revision of its 2025 profit forecast due to China’s reimbursement policy shifts indirectly highlighted regulatory risks that could affect diagnostic demand for Abbott and peers.

Market fundamentals remain robust, with Abbott’s recent Q2 earnings showing 7.37% year-on-year revenue growth and a 399th consecutive quarterly dividend. The company’s expansion into biosimilars and emerging markets, including partnerships with MAbxience, further strengthens its long-term outlook. However, challenges such as high device costs and regulatory complexities in key regions remain headwinds for the broader medical technology sector.

A backtested trading strategy involving the top 500 stocks by daily volume yielded a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53% with a CAGR of 31.89% and a Sharpe ratio of 1.14.